CompletedPhase 1NCT01164709
Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer
Studying Acute mast cell leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Swiss Cancer Institute
- Principal Investigator
- Christoph Driessen, MDCantonal Hospital of St. Gallen
- Intervention
- bortezomib(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2010 – 2013
Study locations (4)
- Inselspital Bern, Bern, Switzerland
- Kantonsspital Graubuenden, Chur, Switzerland
- Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland
- Kantonsspital - St. Gallen, Sankt Gallen, Switzerland
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01164709 on ClinicalTrials.govOther trials for Acute mast cell leukemia
Additional recruiting or active studies for the same condition.